What Is the Best Antidepressant for Anhedonia?

No single antidepressant is proven best for everyone who has lost the ability to enjoy things, but some kinds have a clear edge. Medicines that lift dopamine and noradrenaline, the brain’s motivation and drive signals, tend to help loss of pleasure more than the most commonly prescribed antidepressants.¹ That matters because many people find their usual antidepressant eases sadness while leaving the flatness behind, which is a reason to revisit treatment rather than accept it.

Why Standard Antidepressants Often Leave Pleasure Behind

Anhedonia is the medical word for losing interest in or pleasure from things you used to enjoy. The brain handles enjoying a reward, judging what it’s worth, and deciding how much effort it deserves in linked but separate regions.² People with more anhedonia are also less willing to put in effort to earn a reward.³ So anhedonia often shows up as “I can’t be bothered” as much as “nothing feels good.”

SSRIs, the most prescribed antidepressants, include sertraline, escitalopram and fluoxetine. They mainly raise serotonin. Serotonin is only one of several chemical signals involved in mood, and the drive to seek out and work for rewards leans heavily on dopamine, which SSRIs do not directly raise. That is why some people describe their depression as “lifted” while they still lack get-up-and-go: the treatment improved one set of symptoms and left another untouched. It doesn’t mean the SSRI failed; the remaining symptom may need a different or additional approach.

SSRIs can also add a numbness of their own. Emotional blunting, a narrower and duller range of feelings, is frequently reported on them.⁴ This numbness may stand in the way of a full recovery even when low mood improves.⁵

Medication numbness and depression’s own flatness can feel alike. Blunting often feels like being shielded from both bad and good feelings, not just sad ones, and it may appear or worsen after you start an SSRI or raise the dose. The anhedonia of depression usually was there before treatment began. Writing down when the flatness started helps your doctor sort out which one you are dealing with.

Low mood and lost pleasure can improve at different speeds, and leftover flatness is a specific symptom doctors can target with a change of medicine. Don’t stop an SSRI suddenly, though. Withdrawal effects are common, so any change should be a taper planned with your doctor.

Bupropion and Other Dopamine-Boosting Antidepressants

Bupropion (Wellbutrin) is the most common first choice for pleasure and drive. It works on dopamine and noradrenaline rather than serotonin, and boosting those signals appears particularly useful for people with pronounced anhedonia.⁶ In a trial, bupropion improved anhedonia more than placebo, and anhedonia was the symptom where dummy pills helped least.⁷

“Dopamine-acting” here means bupropion mainly slows the removal of dopamine and noradrenaline from the gaps between nerve cells, leaving more of each available. Noradrenaline is tied to alertness and energy, so people sometimes notice more energy before they notice more enjoyment. Because bupropion works through different chemicals than an SSRI, the two can be combined without doing the same job twice, and it is often added to an existing SSRI rather than replacing it.

Dose and time shape what improves. Lower doses and earlier weeks of bupropion mainly eased the absence of good feelings.⁸ The return of strongly positive feelings like enthusiasm tended to need higher doses and more time.⁹ Judging bupropion after only a couple of weeks at a starting dose may be too soon, and stopping at the first sign of partial benefit can mean leaving before the fuller effects have appeared. Venlafaxine, which raises noradrenaline as well as serotonin, has also looked useful for marked anhedonia.¹⁰

If you try bupropion, your doctor may add it to your SSRI or switch you gradually. It is less likely than SSRIs to cause sexual side effects or weight gain. Common early effects include trouble sleeping, dry mouth and feeling jittery. It is not suitable for people with seizure disorders or eating disorders like bulimia. Tell your doctor plainly that pleasure and motivation are your main problem, and ask how long and at what dose to try an option before judging.

Esketamine and Ketamine When Other Treatments Fail

Esketamine, sold as Spravato nasal spray, is the first FDA-approved rapid-acting treatment for depression and is based on ketamine.¹¹ Ketamine can ease depression, including anhedonia, often within hours.¹² It helps in about 70% of people with treatment-resistant depression, meaning depression that hasn’t improved with other treatments.¹³ In one clinic study, esketamine’s effect on anhedonia was clear 24 hours after the first dose and grew with repeated treatments.¹⁴

Ketamine and esketamine eased anhedonia about equally in bipolar and unipolar depression.¹⁵¹⁶¹⁷ Mouse research offers one possible explanation: ketamine changes the strength of connections between nerve cells in the brain’s reward hub.¹⁸ Exactly how it relieves anhedonia isn’t fully understood, though.¹⁹ And unlike SSRIs, esketamine left emotional responsiveness intact rather than blunted.²⁰

Treatment happens in a certified clinic, not at home. You stay about two hours to be monitored for dizziness, dissociation and blood pressure changes, and you cannot drive until the next day. It is usually used alongside an oral antidepressant.

Many people feel detached, floaty or dreamlike for part of the session, as though watching events from a distance. These effects usually fade within a couple of hours, which is the reason monitoring is built into each visit. Other common effects include dizziness, nausea and a temporary rise in blood pressure, which staff check during the session.

Treatment usually starts with sessions twice a week for the first month, then tapers to weekly and later every other week as symptoms allow. Your clinic reviews at regular points whether the benefit justifies continuing, since this is an ongoing treatment rather than a one-time fix.

It is typically offered to people who have tried at least two antidepressants without enough benefit, and insurance often requires proof of those earlier tries. A history of substance misuse or uncontrolled high blood pressure may rule it out.

Add-On Medicines That Target Dopamine Directly

An add-on is a second medicine taken alongside your current antidepressant, not a replacement. It suits people whose sadness has improved but whose loss of pleasure remains, since you keep what is working. Because it adds a second drug, side effects and interactions are checked more carefully than with a simple switch.

Pramipexole, a dopamine-mimicking drug usually used for Parkinson’s and restless legs, reduced anhedonia more than placebo in a trial of anhedonic depression.²¹ People taking it became somewhat more physically active.²² It was generally well tolerated and looks promising as an add-on to existing treatment.²³ It is not a routine first move, though. It is approved for Parkinson’s and restless legs, not depression, so using it for anhedonia is off-label. Doses start low and rise slowly, which helps limit nausea and sleepiness. Anyone taking it should watch for new compulsive urges, such as gambling or overspending, and tell the prescriber right away.

Cariprazine (Vraylar), approved for bipolar depression, improved anhedonia in people with bipolar I depression across three trials.²⁴ It seems to work mainly through one dopamine receptor type, D3, which lower doses target most selectively.²⁵ In animal studies, its anti-anhedonia effect disappeared without D3 receptors.²⁶²⁷ Cariprazine belongs to the antipsychotic group, though at depression doses it acts as a mood treatment, not a treatment for psychosis. Because the evidence comes from bipolar I depression, it shouldn’t be assumed to work the same in unipolar depression. It can cause restlessness, an inability to sit still, and reporting it early lets the dose be adjusted.

MAOIs are an older antidepressant class. People with “atypical” depression, which features mood that brightens with good news plus oversleeping and overeating, often respond well to them after other drugs fail.²⁸ MAOIs require avoiding aged cheeses, cured meats and many drug combinations, because some foods can cause dangerous blood pressure spikes and some drug combinations can cause serious reactions.

When Inflammation May Be Driving the Problem

Inflammation in the body can affect brain circuits that drive pleasure and motivation, especially dopamine signalling.²⁹ Anhedonia is common in conditions like diabetes, rheumatic disease and Parkinson’s.³⁰ CRP is a routine blood test for inflammation. In one trial, anti-inflammatory treatment reduced anhedonia only in people with CRP above 3 mg/L.³¹ People with both high CRP and higher cholesterol responded best to anti-inflammatory or dopamine-boosting treatments.³²

CRP is a general marker, so a high result doesn’t say where the inflammation comes from. Infections, injuries, obesity and other illnesses can raise it temporarily, so a single high reading may be repeated before anyone draws conclusions. The 3 mg/L figure is a research cutoff for who responded, not a diagnosis of inflammatory depression.

Anti-inflammatory drugs for anhedonia are not standard treatment yet. If you have an inflammatory illness, mention it to the prescriber. Asking whether an inflammation blood test makes sense is reasonable, and if inflammation is high, treating weight, sleep and diet may matter more.

How Doctors Track Whether Pleasure Is Returning

The Snaith-Hamilton Pleasure Scale, or SHAPS, is a 14-item questionnaire about enjoying everyday things such as food, hobbies and company. It reliably measures enjoyment specifically in adults with hard-to-treat depression.³³ It is the main yardstick in many anhedonia trials, including pramipexole and navacaprant.³⁴³⁵

You rate how much you agree with statements such as enjoying a favorite meal or a warm bath. It focuses on recent enjoyment, not on how sad you feel, and takes only a few minutes.

A general mood score alone can miss anhedonia. Those scales mix sadness, sleep, appetite and guilt, so your total can improve while enjoyment stays low. A pleasure-specific measure picks up that gap, which is why asking your doctor to track pleasure separately can be useful.

You can track progress yourself too. Note weekly which small things felt good or worth doing, and watch effort as well as enjoyment, since starting tasks counts. Expect partial gains before full ones, and bring your notes to appointments so dose decisions rest on more than memory.

Newer Medicines and Non-Drug Options

A new drug class blocks kappa-opioid receptors, which respond to a stress chemical that dampens reward.³⁶ Blocking it is meant to release that brake rather than add more dopamine, a different route for people who did not respond to the usual medicines. In an 8-week trial, one such drug improved reward-related brain activity, learning from rewards, and anhedonia.³⁷ Navacaprant improved anhedonia more than placebo at 4 and 8 weeks.³⁸ Aticaprant improved anhedonia when added to an SSRI or SNRI.³⁹ These drugs are not yet approved. Trials recruit people with depression, and ClinicalTrials.gov lists studies by location. Ask your psychiatrist whether you qualify and what the placebo risk means. Psilocybin increased reward responsiveness for at least a day in rats, but human evidence for anhedonia is still early.⁴⁰

Behavioural activation is a therapy that schedules rewarding activities step by step, even before motivation returns. Anhedonia lowers the urge to start things, so waiting for motivation keeps you stuck. Small planned activities rebuild the link between effort and reward, and tiny, specific tasks such as a ten-minute walk work best. Medication can make this easier, and the two combine well. Combined with TMS, a magnetic brain stimulation treatment, people completed about 77% of their goals and their anhedonia scores fell by about 39%.⁴¹

1
PubMed Central. Anhedonia: Current and future treatments ↩︎
2
PubMed Central. The Neurobiology of Anhedonia and Other Reward-Related Deficits ↩︎
3
PubMed Central. Worth the ‘EEfRT’? The Effort Expenditure for Rewards Task as an Objective Measure of Motivation and Anhedonia ↩︎
4
Current Psychopharmacology. Emotional Blunting in SSRI-Treated Patients vs. Preserved Affective Responsiveness with Esketamine in Treatment-Resistant Depression: A Comparative Study and Review ↩︎
5
Current Psychopharmacology. Emotional Blunting in SSRI-Treated Patients vs. Preserved Affective Responsiveness with Esketamine in Treatment-Resistant Depression: A Comparative Study and Review ↩︎
6
PubMed Central. Anhedonia: Current and future treatments ↩︎
7
PubMed. Assessing the effects of bupropion SR on mood dimensions of depression ↩︎
8
PubMed. Assessing the effects of bupropion SR on mood dimensions of depression ↩︎
9
PubMed. Assessing the effects of bupropion SR on mood dimensions of depression ↩︎
10
PubMed Central. Anhedonia: Current and future treatments ↩︎
11
Brain & Behavior Research Foundation. Researchers Trace How Ketamine Acts on Specific Brain Circuits and Synapses to Relieve Anhedonia ↩︎
12
Brain & Behavior Research Foundation. Researchers Trace How Ketamine Acts on Specific Brain Circuits and Synapses to Relieve Anhedonia ↩︎
13
Brain & Behavior Research Foundation. Researchers Trace How Ketamine Acts on Specific Brain Circuits and Synapses to Relieve Anhedonia ↩︎
14
PubMed. Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression ↩︎
15
PubMed. Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression ↩︎
16
PubMed. Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression ↩︎
17
Journal of Affective Disorders Reports. The anti-anhedonic effects of ketamine in the treatment of resistant unipolar and bipolar depression: A systematic review and meta-analysis of current data ↩︎
18
Brain & Behavior Research Foundation. Researchers Trace How Ketamine Acts on Specific Brain Circuits and Synapses to Relieve Anhedonia ↩︎
19
PubMed. The Use of Ketamine for the Treatment of Anhedonia in Depression ↩︎
20
Current Psychopharmacology. Emotional Blunting in SSRI-Treated Patients vs. Preserved Affective Responsiveness with Esketamine in Treatment-Resistant Depression: A Comparative Study and Review ↩︎
21
PubMed Central. Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial ↩︎
22
PubMed Central. Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial ↩︎
23
PubMed Central. Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial ↩︎
24
PubMed Central. Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials ↩︎
25
PubMed Central. Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials ↩︎
26
PubMed Central. Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials ↩︎
27
CNS Spectrums. The role of dopamine D3 receptors in the mechanism of action of cariprazine ↩︎
28
PubMed Central. Atypical depression: state of the art and future perspectives ↩︎
29
PubMed Central. Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression ↩︎
30
PubMed Central. Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression ↩︎
31
PubMed Central. Lipids and C-reactive protein predict anhedonia and reward circuit functional connectivity responses to anti-cytokine and dopaminergic therapies in patients with depression ↩︎
32
PubMed Central. Lipids and C-reactive protein predict anhedonia and reward circuit functional connectivity responses to anti-cytokine and dopaminergic therapies in patients with depression ↩︎
33
PubMed Central. Evaluation of Anhedonia with the Snaith–Hamilton Pleasure Scale (SHAPS) in adult outpatients with major depressive disorder ↩︎
34
PubMed Central. Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial ↩︎
35
PubMed Central. Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder ↩︎
36
PubMed Central. Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study ↩︎
37
PubMed Central. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS) ↩︎
38
PubMed Central. Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder ↩︎
39
PubMed Central. Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study ↩︎
40
PubMed. Psychedelics produce enduring enhancement of reward responsiveness in male rats ↩︎
41
PubMed. Behavioral activation therapy during transcranial magnetic stimulation for major depressive disorder ↩︎